DES data in high-risk subgroups presented

Picture 5

In addition to addressing the safety and efficacy of drug-eluting stents (DES) in general and relative to one another, randomized controlled trials and registries are now beginning to assess specific lesion subgroups for which DES are not currently approved in the US. These include in-stent restenosis, saphenous vein grafts, bifurcation lesions, left main disease, and acute myocardial infarction. Presenters at the “Enter the Drug-Eluting Stent Revolution V” summit, held in mid March immediately before the annual meeting of the American College of Cardiology, discussed existing data regarding the use of DES for these indications.

Proceedings of TCT 3, 9-11 (2006).
view PDF

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: